Eventide Asset Management LLC Purchases 2,946 Shares of Eli Lilly and Company (NYSE:LLY)

Eventide Asset Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 249.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,128 shares of the company's stock after purchasing an additional 2,946 shares during the quarter. Eventide Asset Management LLC's holdings in Eli Lilly and Company were worth $3,657,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of LLY. International Assets Investment Management LLC boosted its holdings in Eli Lilly and Company by 87,091.7% during the third quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company's stock valued at $11,041,631,000 after purchasing an additional 12,448,888 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Eli Lilly and Company by 2.6% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,115,504 shares of the company's stock valued at $5,417,970,000 after buying an additional 157,741 shares in the last quarter. Fisher Asset Management LLC grew its position in Eli Lilly and Company by 3.5% in the third quarter. Fisher Asset Management LLC now owns 5,058,101 shares of the company's stock valued at $4,481,175,000 after acquiring an additional 169,391 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Eli Lilly and Company by 5.0% during the second quarter. Dimensional Fund Advisors LP now owns 3,581,075 shares of the company's stock valued at $3,242,296,000 after acquiring an additional 171,595 shares during the period. Finally, Ameriprise Financial Inc. boosted its stake in shares of Eli Lilly and Company by 0.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 3,027,901 shares of the company's stock valued at $2,741,832,000 after purchasing an additional 22,392 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Ratings Changes

LLY has been the subject of a number of recent analyst reports. Citigroup lifted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a "buy" rating in a report on Friday, October 25th. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an "overweight" rating in a research note on Friday, August 9th. Evercore ISI raised Eli Lilly and Company to a "hold" rating in a report on Thursday, September 5th. Sanford C. Bernstein began coverage on Eli Lilly and Company in a report on Thursday, October 17th. They set an "outperform" rating and a $1,100.00 price target for the company. Finally, BMO Capital Markets lifted their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an "outperform" rating in a research report on Friday, August 9th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,007.94.

Eli Lilly and Company Trading Up 0.9 %

Shares of NYSE:LLY traded up $7.16 during mid-day trading on Friday, reaching $795.35. The stock had a trading volume of 2,206,918 shares, compared to its average volume of 3,213,011. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53. The firm has a market cap of $755.04 billion, a PE ratio of 85.98, a price-to-earnings-growth ratio of 2.99 and a beta of 0.43. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The firm has a 50 day simple moving average of $851.90 and a two-hundred day simple moving average of $870.26.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same period in the previous year, the business posted $0.10 EPS. The business's quarterly revenue was up 20.4% compared to the same quarter last year. On average, research analysts predict that Eli Lilly and Company will post 13.2 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.65%. Eli Lilly and Company's payout ratio is 56.22%.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company's stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.